Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Active not recruiting 9Recruiting 5Completed 3Terminated 1

Sponsor Class

OTHER 3NETWORK 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

Specimen Handling 198Magnetic Resonance Spectroscopy 160pembrolizumab 141Carboplatin 117Biopsy 111Cyclophosphamide 93Cisplatin 93Paclitaxel 75Bevacizumab 61Gemcitabine 60Nivolumab 57fludarabine 53Radiotherapy 50Fluorouracil 49Pemetrexed 46Oxaliplatin 43Dexamethasone 43venetoclax 42Rituximab 41Leucovorin 41Doxorubicin 41durvalumab 40Docetaxel 40Capecitabine 39Radiation 37atezolizumab 35Prednisone 32Injections 31Fulvestrant 31Standard of Care 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × niraparib × 30 days × Clear all
NCT05615818 2026-05-19

SAFIR-ABC10

UNICANCER

Phase 3 Recruiting
800 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT05601440 2026-05-07

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Canadian Cancer Trials Group

Phase 2 Recruiting
484 enrolled
Breast

Breast Neoplasms

NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06915025 2026-05-04

OVATION-3

Imunon

Phase 3 Recruiting
500 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡